Allergy Therapeutics PLC Block Listing Return and Total Voting Rights (7751L)
15 Gennaio 2021 - 8:00AM
UK Regulatory
TIDMAGY
RNS Number : 7751L
Allergy Therapeutics PLC
15 January 2021
Allergy Therapeutics plc
("Allergy Therapeutics", "ATL" or the "Group")
Block Listing Return and Total Voting Rights
Block Listing Return
Allergy Therapeutics plc (AIM: AGY), the fully integrated
commercial biotechnology company specialising in allergy vaccines,
makes the following update on its block listings, pursuant to AIM
Rule 29 and Schedule Six of the AIM Rules for Companies.
Name of applicant: ALLERGY THERAPEUTICS PLC
Name of scheme: Allergy Therapeutics plc 2013 Long Term Incentive Plan
------------------------------------------------------------------
Period of return: From: 2 July 2020 To: 15 January 2021
----------------------- ------------------------ -------------- ------------------------
Number and class of share(s) (amount of stock / 10,000,000 ordinary shares of 0.1p each in the Company admitted
debt securities) originally listed and the to trading on 24 November
date of admission: 2017
------------------------------------------------------------------
Balance of unallotted securities under scheme(s)
from previous return: 6,831,964
------------------------------------------------------------------
Plus: The amount by which the block scheme(s) has -
been increased since the date of the last
return (if any increase has been applied for):
------------------------------------------------------------------
Less: Number of securities issued/allotted under
scheme(s) during period: 3,506,360
------------------------------------------------------------------
Equals: Balance under scheme(s) not yet
issued/allotted at end of period: 3,325,604
------------------------------------------------------------------
Name of contact: Sara Goldsbrough
Telephone number of contact: +44 (0) 7966 165719
--------------------
Total Voting Rights
Allergy Therapeutics also announces that pursuant to its block
admission facility, details of which were announced on 20 November
2017, it has recently issued 928,437 ordinary shares of 0.001 pence
each ("Ordinary Shares") in satisfaction of the exercise of share
options. The new Ordinary Shares rank pari passu with the Company's
existing shares.
In accordance with DTR 5.6.1 of the Financial Conduct
Authority's Disclosure Guidance and Transparency Rules, as at 15
January 2021, the Company has 640,792,164 Ordinary Shares in issue.
There are no shares held in treasury. The total number of voting
rights in the Company is therefore 640,792,164.
The above figure of 640,792,164 may be used by shareholders in
the Company as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change in their interest in, the share capital of the Company
under the FCA's Disclosure Guidance and Transparency Rules.
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Rupert Dearden, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Nicholas Brown / Olivia
Manser
allergytherapeutics@consilium-comms.com
Stern Investor Relations, Inc.
+1 212 362 1200
Christina Tartaglia
christina@sternir.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial
biotechnology company focussed on the treatment and diagnosis of
allergic disorders, including aluminium free immunotherapy vaccines
that have the potential to cure disease. The Group sells
proprietary and third-party products from its subsidiaries in nine
major European countries and via distribution agreements in an
additional ten countries. Its broad pipeline of products in
clinical development include vaccines for grass, tree and house
dust mite, and peanut allergy vaccine in pre-clinical development.
Other adjuvant systems to boost performance of vaccines outside
allergy are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with more than 11,000m(2) of
state-of-the-art MHRA-approved manufacturing facilities and
laboratories. The Group, which has achieved double digit compound
annual growth since formation, employs c.500 employees and is
listed on the London Stock Exchange (AIM:AGY). For more
information, please see www.allergytherapeutics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRFLFITLAISLIL
(END) Dow Jones Newswires
January 15, 2021 02:00 ET (07:00 GMT)
Grafico Azioni Allergy Therapeutics (LSE:AGY)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Allergy Therapeutics (LSE:AGY)
Storico
Da Apr 2023 a Apr 2024